Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deutenzalutamide - Hinova Pharmaceuticals

Next Previous
Drug Profile

Deutenzalutamide - Hinova Pharmaceuticals

Alternative Names: Deuterated enzalutamide; Enzalutamide deuterated; HC 1119

Latest Information Update: 27 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hinova pharmaceuticals
  • Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Fluorobenzenes; Imidazoles; Imidazolidines; Nitriles; Organic deuterium compounds; Small molecules; Thiones
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Prostate cancer
  • Phase III COVID 2019 infections
  • No development reported Breast cancer

Most Recent Events

  • 10 Jul 2023 Preregistration for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in China (PO) (Hinova Pharmaceuticals, pipeline July 202)
  • 02 Jun 2023 Efficacy and adverse events data from a phase III trial in Prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 28 Dec 2022 No recent reports of development identified for preclinical development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease) in China (PO, Capsule)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top